Результаты поиска

The potential of oral healthcare providers to recognise early systemic disease.

Like many other body structures, the mouth is often affected by disease that principally arises from, or targets, several tissue sites. Indeed, systemic disorders can manifest on the oral mucosa as the first, only, or become the most severe manifestation of a systemic disease and/or become the most significant factor to adversely affect an individual's quality of life. Oral healthcare providers (dentists, therapists and hygienists) may be the first to observe an abnormality in the mouth which sometimes indicates a significant systemic disease unknown to the patient or their general medical pra

Is Systemic Immunosuppression a Risk Factor for Oral Cancer? A Systematic Review and Meta-Analysis.

Even if the relationship between immunosuppression and increased incidence of systemic cancers is well known, there is less awareness about the risk of developing oral cancer in immunosuppressed patients. The aim of this review was to evaluate the association between immunosuppression and the development of oral cancer. Two authors independently and, in duplicate, conducted a systematic literature review of international journals and electronic databases (MEDLINE via OVID, Scopus, and Web of Science) from their inception to 28 April 2023. The assessment of risk of bias and overall quality of e

Совпадение в полном тексте источника
… variable immunodeficiency, severe combined immunodeficiency, DiGeorge syndrome, and congenital hypogammaglobulinemia), systemic diseases (e.g., autoimmune diseases, diabetes, chronic infections, and solid and liquid malignancies, such as leukemia, lymphoma, and multiple myeloma), and pharmacological … OR lymphoma) AND “Oral Cancer”), (“Oral Carcinoma” AND (immunosuppression OR malnutrition OR infections OR autoimmune disease OR X-linked agammaglobulinemia OR common variable immunodeficiency OR selective immunoglobulin A deficiency OR hyper IgM syndrome OR DiGeorge syndrome OR severe combined immunodeficiency …

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies.

Primary Immunodeficiencies (PID) are a group of rare congenital disorders of the immune system. Autoimmune cytopenia (AIC) represents the most common autoimmune manifestation in PID patients. Treatment of AIC in PID patients can be really challenging, since they are often chronic, relapsing and refractory to first line therapies, thus requiring a broad variety of alternative therapeutic options. Moreover, immunosuppression should be fine balanced considering the increased susceptibility to infections in these patients. Specific therapeutic guidelines for AIC in PID patients are lacking. Treatm

Совпадение в полном тексте источника
… Actually, AIC are rare in patients with “typical” severe combined immune deficiency (SCID), while they are really common in patients with combined immune deficiency (CID), common variable immunodeficiency (CVID) or atypical SCID (AS) ( 2 , 4 ). … Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol (2011) 155:498–508. doi: 10.1111/j.1365-2141.2011.08880.x 31. Kane RC, Bross PF, Farrell AT, Pazdur R, Velcade: US. …

Иммуноглобулиновые добавки и более длинные интервалы дозирования уменьшают риск инфицирования пациентов с ОРМ, обработанных теклистамбом.

Пациенты с реактивной/редактированной множественной миеломой (RRMM), которые проходят курс лечения с использованием диалектических антител (BSAbs) на базе BCMA, подвергаются повышенному риску инфицирования. Предыдущие исследования показали, что лечение иммуноглобулином внутривенно снижает риск серьезных инфекций. Однако вопрос о том, сокращает ли ИГИ инфекцию всех классов и имеет ли место воздействие более продолжительных интервалов дозирования на риск инфицирования, остается неизвестным. Для решения этой проблемы мы провели ретроспективное расследование 80 Пациенты с RRMM, которых лечили текл

Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma.

PurposePrimary effusion lymphoma (PEL) is a type of body cavity-based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.Materials and methodsWe retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.ResultsLatency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, si

The Production Processes and Biological Effects of Intravenous Immunoglobulin.

Immunoglobulin is a highly diverse autologous molecule able to influence immunity in different physiological and diseased situations. Its effect may be visible both in terms of development and function of B and T lymphocytes. Polyclonal immunoglobulin may be used as therapy in many diseases in different circumstances such as primary and secondary hypogammaglobulinemia, recurrent infections, polyneuropathies, cancer, after allogeneic transplantation in the presence of infections and/or GVHD. However, recent studies have broadened the possible uses of polyclonal immunoglobulin showing that it ca

Совпадение в полном тексте источника
… Primary immunodeficiency (PID) disorders, such as agammaglobulinaemias, hyperimmunoglobulin M (IgM) syndromes and common variable immunodeficiencies (CVID), are either caused by defined gene mutations or remain molecularly undefined [ 7 , 8 ]. … Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency J Allergy Clin. Immunol. 2002 109 1001 1004 10.1067/mai.2002.124999 12063531 105. Raanani P. Gafter-Gvili A. Paul M. Ben-Bassat I. Leibovici L. Shpilberg O. …

Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.

BackgroundPneumocystis jirovecii pneumonia (PJP) is a life-threatening infection occurring in patients receiving bendamustine. The poorly defined incidence, particularly when utilizing polymerase chain reaction (PCR)-based diagnostic techniques, precipitates unclear prophylaxis recommendations. Our objective was to determine the cumulative incidence of PJP diagnosed by single copy target, non-nested PCR in patients receiving bendamustine.MethodsPatients were evaluated for PJP from initiation of bendamustine through 9 months after the last administration. The cumulative incidence of PJP was est

Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy.

IntroductionHuman immunoglobulins are the standard of care for patients with immunodeficiencies and represent a first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to evaluate costs associated with facilitated subcutaneous (fSCIG), conventional subcutaneous (cSCIG), and intravenous (IVIG) administration of immunoglobulin in patients with primary or secondary immunodeficiency (PID and SID, respectively) and in patients with CIDP in Italy.MethodsA cost-minimization analysis from a societal perspective was developed, considering a one-year follow-up

Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.

BackgroundPatients with chronic lymphocytic leukemia (CLL) experience hypogammaglobinemia and non-neutropenic infections. In this exploratory proof of concept study, our objective was to determine the prevalence of humoral immunodeficiency in patients with CLL and serum IgG ≥ 400 mg/dL, and to evaluate the efficacy of subcutaneous immunoglobulin (SCIG) in this population.Patients and methodsPatients with CLL with serum IgG ≥ 400 mg/dL were evaluated for serum IgG, IgM, IgA, along with pre/post vaccine IgG titers to diphtheria, tetanus, and Streptococcus pneumoniae. Patients with evidence of hu

Ремдезивирско-ассоциированные результаты выживания среди иммунокомпромиссных пациентов, госпитализированных COVID-19: Реальные улики о микродоминантной эпохе.

Пациенты с иммунокомпромиссными заболеваниями подвергаются повышенному риску заболевания коронавирусом 2019 (В тыс.COVID-19) связанная с этим госпитализация и смерть. Случайные клинические испытания обеспечивают ограниченное число пациентов, если таковые имеются, для получения информации о результатах лечения таких пациентов ремдезивиром. COVID-19 в период с декабря 2021 и февраль 2024. Главным результатом этого стало то, что стационарная смертность была проверена у пациентов, у которых характерные показатели сравниваются с оценками, в группах ремдесивир против нередесивирных групп. Были прове

Economic impact of immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer: a single center observational study.

This is the first report of the health economic benefits derived from preventing infections through Immunoglobulin Replacement Therapy (IgRT) in patients with secondary immunodeficiency due to hematological malignancies. We conducted a retrospective population-based cohort study using patient medical history and pharmacy data from the Hospital Clínico San Carlos for 21 patients between 2011 and 2020. The pharmacoeconomic impact of using prophylactic IgRT was assessed by comparing characteristics of the SID patients 1 year before and after initiating IgRT measured by direct medical and tangible

Совпадение в полном тексте источника
… Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment . …

Удельный возрастной риск герпеса у взрослых ≥18 Годы с совместимыми условиями - Ретроспективное когертное исследование в Соединенных Штатах.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: ДОЛЖНОСТНЫЕ ЛИЦА≥50 Возраст [YoA] и иммунокомпромиссные взрослые подвергаются повышенному риску заболевания герпесом зостером (HZ). Вместе с тем те, у кого есть связи, также подвергаются повышенному риску, однако в последнее время США не располагают достаточными доказательствами, особенно в том, что касается 18-49 Йоа. МЕТОДЫ: Это ретроспективное когортное исследование США2015-2022, " Merative MarketScan Commercial and Medicare upal " ( < < Профессиональный рынок > > ) сравнивает показатели заболеваемости ВЗ (ИР) у молодых иммунокомпетентных взрослы

Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.

Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral disease of the brain-caused by human polyomavirus 2. It affects patients whose immune system is compromised by a corresponding underlying disease or by drugs. Patients with an underlying lymphoproliferative disease have the worst prognosis with a mortality rate of up to 90%. Several therapeutic strategies have been proposed but failed to show any benefit so far. Therefore, the primary therapeutic strategy aims to reconstitute the impaired immune system to generate an effective endogenous antiviral response. Recently, an

Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.

BACKGROUND Infections are the main cause of mortality and morbidity in multiple myeloma (MM) patients. However, adult immunodeficiency specialists in China are lacking, and the care of secondary immunodeficiency (SID) and the prognostic role of hypogammaglobulinemia in MM is unknown. MATERIAL AND METHODS MM patients (295) were retrospectively analyzed between January 2012 and 2020 in Zhejiang Provincial People's Hospital, Hangzhou Medical College. MM patients with immunoglobulin (Ig) G <5 g/L were defined as SID patients. The care of these patients and the prognostic role of IgG <5 g/L were an

Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.

BackgroundDespite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population.ObjectiveTo describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT).MethodsA cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographi

Совпадение в полном тексте источника
… Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010. Jun;125(6):1354–1360.e4. doi: 10.1016/j.jaci.2010.02.040 9. Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G. …

Evidence for the use of intravenous immunoglobulins--a review of the literature.

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel

Breaking into HIV-1's Epigenetic Vault: Cure Strategies to Eliminate the Viral Reservoir.

Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that integrates into the host cell's DNA as a provirus. Transcription from the provirus is regulated in large part by cellular proteins and epigenetic factors. These may be repressive or permissive to productive infection. The host factors that regulate this balance are therefore attractive targets for HIV-1 therapeutics. Indeed, proviral chromatin is the focus of two of the current HIV-1 cure strategies. "Shock and Kill" uses latency reversal agents to open the provirus's chromatin, promoting high levels of gene expression that induc

Extranodal Involvement of the Anorectal Region in an HIV-Positive Patient With Plasmablastic Lymphoma: A Case Report.

Plasmablastic lymphoma (PbL) is a rare type of aggressive B-cell malignancy that has an extremely poor prognosis without chemotherapeutic treatment, requiring a high degree of suspicion for an early and accurate diagnosis. It has been classically described in patients infected with the human immunodeficiency virus (HIV). However, it accounts for only 2.6% of acquired immunodeficiency syndrome (AIDS)-related lymphomas. Extranodal involvement is most commonly seen within the oral cavity (44%). Involvement of the gastrointestinal tract (14%) is rare and can often be confused with other malignanci

Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar i

Совпадение в полном тексте источника
… Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010) 125(6):1354–1360e1354. 10.1016/j.jaci.2010.02.040 125. … Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol (2009) 145(6):709–27. 10.1111/j.1365-2141.2009.07669.x 139. Cunningham-Rundles C. …